Cancer
-
Randomized Controlled Trial Clinical Trial
Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
A single-institution, randomized open trial was prospectively performed to compare orally administered granisetron with or without intramuscularly administered methylprednisolone to metoclopramide plus methylprednisolone in the prevention of delayed nausea and vomiting induced by cisplatin-based chemotherapy. The effects of antiemetic treatments were evaluated from days 2 to 5 of the first cycle after cisplatin administration among patients who had never before received chemotherapy. ⋯ These data suggest that orally administered granisetron with or without methylprednisolone may be given safely to patients with cancer as prophylactic therapy against delayed emesis after high dose cisplatin therapy. Orally administered granisetron alone was less active than a standard combination of metoclopramide plus methylprednisolone. However, the addition of corticosteroid to orally administered granisetron improved the control of delayed emesis. The efficacy of the combination of metoclopramide plus methylprednisolone and oral granisetron with or without methylprednisolone against delayed emesis still is not entirely satisfactory.
-
The three most extensively evaluated screening methods for ovarian cancer are pelvic examination, serum CA 125, and transvaginal sonography (TVS). The lack of sensitivity of pelvic examination and serum CA 125 has limited their use in ovarian cancer screening. Currently, the most effective screening method for ovarian cancer is TVS. ⋯ Transvaginal sonography screening causes a decrease in stage at detection and a decrease in case-specific mortality. Further study is needed to determine if annual TVS screening will significantly reduce ovarian cancer mortality. The cost for TVS screening is reasonable and is well within the range of that reported for other screening tests.
-
More than 250,000 women will die of cancer in the United States this year, almost 10% of which are due to gynecologic malignancies. Many of these women will have received care in the intensive care unit (ICU). With important advances in medical technology and the advent of an expanded pharmacologic armamentarium, our ability to maintain life has increased greatly over the past few years. ⋯ Decisions regarding admission to an ICU, level of care, and termination of care must take into account patient and family wishes, a reasonable estimation of the reversibility of the acute disease process in question, and the natural history of the underlying disease. Many prognostic scoring systems have been devised to estimate the probability of death among adult ICU patients; however, most of these systems were developed with data from trauma patients rather than from patients with an underlying malignancy, and none are capable of predicting which patient will die. Decisions concerning level of care in the ICU will necessarily involve medical as well as ethical considerations and are best made with a team approach.
-
Clinical Trial
Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate.
In recent years, the routine use of prostate-specific antigen (PSA) to detect cancer of the prostate (CaP) early has renewed the controversy regarding radiotherapy versus radical prostatectomy as the superior definitive treatment. Radiotherapy alone has been reported to result in a high incidence of local recurrence, whereas on the other hand surgical treatment has resulted in a high incidence of microscopic residual tumor. The purpose of this study was to review our treatment results with radical prostatectomy followed by planned courses of postoperative irradiation in patients with pathologic Stage (PS) C disease. ⋯ Based on this experience, moderate dose adjuvant radiotherapy after radical prostatectomy in patients with PS C CaP is recommended.